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Abstract 
 
Nephropathic cystinosis is a rare recessive disease characterised by raised lysosomal 
levels of cystine in the cells of all organs. It is treated by regular oral administration of 
the aminothiol, cysteamine.  Corneal crystal deposition is one of the most troublesome 
complications affecting patients and requires the hourly administration of cysteamine 
eye drops.  In an attempt to reduce this frequency and improve the treatment, the 
preparation and evaluation of cysteamine containing hyaluronate gel is reported.  The 
tests demonstrated that the novel gel formulation is non-irritant to the ocular tissues, 
in line with saline solution (negative control). In conclusion these results demonstrate 
that cysteamine can be formulated as an ocular applicable gel formulation.   
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1.0 Introduction 
 
Nephropathic cystinosis is a rare autosomal recessive disease caused by a 
homozygous mutation in the CTNS gene which codes for cystinosin, a lysosomal 
membrane transport protein for cystine1.  As a result, cystine cannot egress the 
lysosome and instead accumulates and crystallises, ultimately causing organ damage.  
Cystine crystals accumulate in almost all organs and tissues in the body, although the 
kidneys and eyes are particularly susceptible2.  The main clinical parameter for 
diagnosis and long-term monitoring is extremely high levels of leukocyte cystine3.  
The disease results in death from renal failure by the second decade of life unless 
cystine levels can be reduced and kept within acceptable limits (< 1 nmol half-
cystine/mg protein). The main symptoms of the condition are poor growth, renal 
Fanconi syndrome, renal glomerular failure and impairment of other tissues and 
organs.  If oral cysteamine treatment is initiated just after birth this may attenuate the 
rate of renal failure, however, glomerular damage present at the time of diagnosis is 
irreversible and may result in the need for kidney transplant4-7.  
 
Although novel prodrug strategies are being researched8 the main treatment for the 
disorder remains the oral administration of the aminothiol, cysteamine (figure 1) (as 
the bitartrate salt, Cystagon).  The molecule lowers intracellular levels of cystine by 
forming a cysteamine–cysteine mixed disulfide. The disulfide is spatially and 
structurally similar to the amino acid lysine and can egress the lysosome using the 
undamaged excretion pathway for lysine9.  Due to a lack of vasculature in the cornea, 
the oral form of cysteamine has no effect on depleting corneal crystals, thus 
cysteamine must also be applied topically in the form of eye drops10. 
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Figure 1. Cysteamine 
 
Corneal crystal deposition is one of the most troublesome complications affecting 
patients, especially as their prognosis improves and life expectancy increases.  
Crystals deposit in the cornea slowly from birth through infancy until they become a 
problem, usually around the age of 6-8 years11.  Photophobia and, ultimately, 
blepharospasm affect the quality of life such that any sunlight can be debilitating.  
The crystals’ accumulation over a period of years can cause corneal scars, keratitis 
and cataracts, as well as band keratopathies to form12.   
 
The current treatment for the corneal crystals is an ophthalmic solution of cysteamine 
hydrochloride, which has demonstrated efficacy in depleting corneal crystals 
following compliant treatment11,12.  However, the eye drops have to be administered 
every hour while awake in order to achieve maximum benefit, with a large treatment 
gap overnight.  When inserted, the eye drops cause discomfort, due the low pH of the 
drops13.  Despite excellent patient compliance, eye drops are rapidly drained from the 
ocular surface.  In order to improve the bioavailability of ophthalmic delivery 
systems, slow the progression of crystal deposition, while also allowing freedom from 
an 8 to 15-a-day dosing schedule, it is desirable to prolong ocular residence time and 
encourage site-specific delivery through sustained drug release. Ophthalmic gels may 
provide a viable alternative to the current eye drop formulation.   
 
An eye gel has been developed and characterised in our laboratories14.  Part of this 
process is to elucidate the ophthalmic irritation potential of the eye gel.  One model 
for this is the Draize Rabbit Eye Test, which is very invasive and involves the 
slaughter of the adult rabbit, and subsequent removal of the rabbit eye15,16.  The 
alternative for this test is the hens’ eggs test using the chorioallantoic membrane 
(HET-CAM test), an inexpensive and sensitive assay which uses fertilised hens’ 
eggs17.  The HET-CAM test is an established test for ophthalmic irritancy, and has 
shown good correlation to ophthalmic irritation in the vivo situation15,18-20.  The 
membrane separates the embryo from the airspace, and is non-innervated, highly 
vascularised and responds to injury in a similar way to rabbit conjunctiva16,20.  The 
HET-CAM test sits between in vivo and in vitro techniques, and is not a licensed 
procedure.   
The ophthalmic gel formulation reported in this paper has the potential to provide an 
effective treatment for the corneal crystals, due to its bioadhesive and pseudoplastic 
properties, while relieving the discomfort which is currently experienced by 
formulating an isotonic gel at pH7.4.  The ophthalmic gel may also allow fewer doses 
to be administered, lessening the dosage burden through prolonged contact with the 
cornea.  Sodium hyaluronate is a natural, high molecular weight polymer which is 
expressed in human vitreous humour21, and therefore provides an inherent 
biocompatibility with the eye22.  It also promotes wound healing23, and has been used 
commercially in artificial tears preparations for over 30 years23 and has an established 
safety record21. 
 
Current understanding of ocular pharmacokinetics involves mixing of the eye drops 
with lachrymal fluid, produced at a rate of 0.5-2.2 µL/min24,25, resulting in a short 
contact time with ocular tissue.  Subsequent drainage towards the nasolachrymal duct 
during blinking results in extensive elimination of the applied solution and contact 
times varying from 1-2 minutes26,27 to 5 minutes28-30  have been reported.  The rapid 
drainage rate is due to the tendency of the eye to maintain its residence volume at ~10 
µL, and consequently, the overall absorption and bioavailability of a topically applied 
drug is typically less than 5%31,32.  An ophthalmic gel may overcome these physical 
barriers and improve bioavailability through improved contact time with the corneal 
surface33. 
 
The sodium hyaluronate hydrogel is both transparent and bioadhesive and these 
attributes are highly desirable for topical ophthalmic application34.  Non-Newtonian 
pseudoplastic or ‘shear thinning’ rheology facilitates the process of blinking by 
dramatic reductions in apparent viscosity as a function of the high external shear 
stresses applied by the leading-edge and inside surface of the eye-lid35.  These high 
shear stresses are associated with equivalent shear rates of 0 s-1 at rest to 10,000 - 
40,000 s-1 when blinking36.  Pseudoplastic fluids therefore offer significantly less 
resistance to blinking than Newtonian liquids of equivalent viscosity.  High apparent 
viscosities under zero external stresses result in longer contact times on the surface of 
the eye37.  In addition to these physico-chemical properties, the gel is isotonic due to 
the inclusion of SMPB buffer as an excipient38, and sits at physiological pH7.4, 
minimising the potential for irritation.  For topical ophthalmic formulations of 
cysteamine, these properties should result in less frequent application and better 
patient compliance. 
 
The aim of this work is to elucidate the effect of the eye gel and the current 
ophthalmic solution of cysteamine on the blood vessels of the egg’s chorioallantoic 
membrane (HET CAM test), which demonstrates good correlation with the eye and is 
an established ophthalmic model16.  The outcomes of this study could provide 
rationale for the usefulness of the gel in the treatment of the ophthalmic complications 
of cystinosis.  
  
 
2.0 Materials and methods 
2.1 Materials 
 
Cysteamine hydrochloride and benzalkonium chloride were purchased from Sigma 
(Dorset, UK).  Sodium hyaluronate was obtained from Aromantic Ltd (Moray UK).  
Water for injection (WFI) was made by autoclaving distilled water.  Saline solution 
was made using sodium chloride obtained from Fisher, dissolved in WFI.  Fertilised 
hens’ eggs were obtained from a local breeder.  All procedures conformed to current 
national guidelines: eggs were used within 10 days of incubation.  All other chemicals 
were of general laboratory grade.   
 
 
2.2 Preparation of gels 
 
The medicated gels at pH 7.4 were made by the addition of sodium hyaluronate to 
WFI, which was allowed to fully hydrate overnight at 4˚C.  After stirring for 5 
minutes, the pH of the gel solution was then adjusted to 7.4, by addition of 2M 
hydrochloric acid.  Sorensen’s Modified Phosphate Buffer (SMPB) was added, along 
with cysteamine hydrochloride.  The pH was maintained at 7.4.  Benzalkonium 
chloride was added as a preservative.  The final weight of the gel (20g) was made up 
with WFI.  All gels were allowed to rest at 4˚C for 24h until further testing 
commenced.   
The unmedicated gels were manufactured as above but without cysteamine.  The gels 
with a modified pH were manufactured with 2M NaOH or 2M hydrochloric acid to 
reach the desired pH.  The medicated solutions were made as per the current 
formulation, i.e. cysteamine hydrochloride in a saline solution, with benzalkonium 
chloride as a preservative39,40.  
 
 
 
2.3 HET-CAM test: method 
 
The fertilised hens’ eggs were obtained on day zero.  They were either Dorking-
Wyandotte crosses or Dorking-Rhode Island Red crosses.  The eggs were marked 
with crosses, numbers and dates and incubated at 37±0.5˚C and 40%±5% humidity 
for 9 days41.  The eggs were incubated in the horizontal position to ensure the correct 
positioning of the embryo (away from the CAM).  They were manually rotated 180˚at 
least three times a day for the duration of the test, to ensure correct development and 
viability of the embryo.  The exact time that they were placed in the incubator was 
marked as T0.  On day 9, the eggs were candled to ensure fertility, and the shell was 
marked on the line of the airspace.  When the eggs had been incubated for 10 full 
days, the experiment began.  Each egg was removed individually from the incubator, 
and placed in an egg holder with the larger end upwards. The shell was cut just above 
the marked line of the chorioallantoic membrane using a Dremel® Multitool (Illinois, 
USA), with rotating cutting blade attachment.  Once this section of shell had been 
removed, the inner membrane directly in contact with the CAM was moistened with 
2ml of 0.9% saline solution, added with a pippette.  The inner membrane was then 
carefully removed using forceps, without causing injury to the blood vessels, to reveal 
the chorioallantoic membrane below.  The same volume of test solution was then 
added directly onto the CAM using a pippette, and a timer started.  Any lysis, 
haemorrhaging and/or coagulation at different times over a 5-minute period after 
application of the test solution will be documented, and any effect is noted and 
compared with controls: saline (negative) and sodium hydroxide (positive) solutions.  
Photographs were taken to record qualitative data.  Once this 5-minute period was 
over, the membrane was disrupted, the remains of the egg placed into a sealed bag, 
and the bag placed into the freezer for subsequent incineration.  Each egg was treated 
in this way until all of the eggs had been tested and destroyed.  Each experimental 
protocol was replicated 5 times .  
 
A semi-qualitative analysis was performed using the photographs, where the severity 
of any haemorrhage was graded on a scale from 0 (no reaction) to 3 (strong reaction) 
using the method developed by Gupta et al20.  The photographs, obtained using a 
Canon Powershot digital camera were subsequently analysed using Adobe® 
Photoshop®42 and ImageJ43 (available as freeware from http://rsb.info.nih.gov/ij/) to 
quantify the vascular damage, allowing a more detailed and robust analysis of the gels 
to be made16, 44-46.  
 
2.4 HET-CAM test: quantification using Photoshop® and ImageJ 
 
The photos of the chorioallantoic membranes were loaded individually onto 
Photoshop®, cropped for size, and the image converted to greyscale.  The resulting 
files were then saved individually as TIFF files with no layers44.  
 
To quantify the extent of any haemorrhaging, the TIFF files formed using Photoshop® 
were loaded into ImageJ.  To analyse the greyscale values of the pixels over a 
standardised length of membrane, the menu option ‘Lines’ was selected, and a straight 
line drawn across the image.  The profile of the average grey pixel value along the 
drawn line was plotted, and the length of the line adjusted to a uniform length.  The 
menu option ‘List’ was selected and the values copied into Microsoft® Excel® 
(Washington, USA).  This process was repeated for all images, and the average pixel 
grey value plotted against distance44.   
 
3.0 Results and discussion 
 
Application of 2ml 0.9% saline solution to the healthy membranes produced no visual 
response over the five-minute period (figure 2).  In contrast, 1M NaOH produced a 
severe, instant haemorrhage, which increased over five minutes (figure 3), grading 
this solution as a severe irritant47. 
 
Figure 2. Sequence of photographs illustrating the effect of 2ml 0.9% saline solution 
(negative control) on the membrane over a 5-minute period. A. Healthy membrane at 
T0, B. Membrane at T0.5minutes, C. Membrane at T1minute, D. Membrane at T2minutes, E. 
Membrane at T4minutes, F. Membrane at T5minutes. 
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 Figure 3. Sequence of photographs illustrating the effect of 2ml 1M NaOH (positive 
control) on the membrane over a 5-minute period. A. Healthy membrane at T0, B. 
Membrane at T0.5minutes, C. Membrane at T1minute, D. Membrane at T2minutes, E. 
Membrane at T4minutes, F. Membrane at T5minutes. 
 
The unmedicated gel at pH7.8 produced a faint reddening of the membrane gradually 
over the time period (Figure 4).  The mildly alkaline nature of the gel (pH7.8) is on 
the upper threshold of ocular tolerance limits (pH6.6-7.8), beyond this range patients 
can experience stinging or discomfort48-51. 
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 Figure 4. Sequence of photographs illustrating the effect of 2ml of unmedicated gel at 
pH7.8 on the membrane over a 5-minute period. A. Healthy membrane at T0, B. 
Membrane at T0.5minutes, C. Membrane at T1minute, D. Membrane at T2minutes, E. 
Membrane at T4minutes, F. Membrane at T5minutes. 
 
The medicated gel at pH7.4 produced no discernable visual changes to the membrane 
(Figure 5).  
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Figure 5. Sequence of photographs illustrating the effect of 2ml of medicated gel at 
pH7.4 on the membrane over a 5-minute period. A. Healthy membrane at T0, B. 
Membrane at T0.5minutes, C. Membrane at T1minute, D. Membrane at T2minutes, E. 
Membrane at T4minutes, F. Membrane at T5minutes. 
 
The medicated gel at pH4.5 caused minor haemorrhage (figure 6).  
 
Figure 6.  The medicated gel at pH4.5 produced a minor haemorrhage over a small 
area of the membrane.   
The unmedicated gel at pH7.4 produced no visible damage (results not shown).  The 
medicated solution at pH6.45 caused no haemorrhaging, however it is interesting to 
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note that there was a marked swelling of the yolk and vitelline membrane (results not 
shown).  This ‘turgidity’ effect was caused by the hypotonic nature of the solution, 
where the cell contains a higher concentration of solutes than the solution, and water 
moves into the cell causing swelling and pain in the eye52.  This solution was made as 
per the formulation of the current eye drop solution, the pH of which was found to be 
higher than the published value of 4.5 at 6.4553.  The irritation experienced by patients 
could be due more to the hypotonic nature of the solution, and subsequent swelling of 
the ophthalmic tissues, rather than the low pH of the drops54.  As a comparison, the 
same ophthalmic solution was tested with a pH of 4.75. 
 
The medicated solution at pH 4.75 caused minor haemorrhaging and turgidity of the 
yolk and vitelline membrane, as well as marked hyperaemia (Figure 7).  Hyperaemia 
is an inflammatory response to an irritant, and the process is similar to that of injured 
rabbit conjunctival tissue20. 
 
Figure 7.  A. Healthy membrane before application of the cysteamine solution, B. The 
low pH and hypotonic nature of the current eye drops caused swelling and minor 
haemorrhaging, as well as hyperaemia.  
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The test solutions can be semi-quantitatively graded using the method developed by 
Gupta et al55.  Each test solution was assigned a grade depending on how much 
haemorrhaging was visible (table 1).  A score of zero was obtained for saline, and 
NaOH recorded a score of 3 (table 2).  
Table 1.  Scoring scale for the HET-CAM test55. 
Effect Score Description 
No visible haemorrhage 
 
0 Non irritant 
Just visible membrane discolouration 
 
1 Mild irritant 
Structures are covered partially by haemorrhage 
 
2 Moderate irritant 
Structures are covered completely by haemorrhage 
 
3 Severe irritant 
 
 
 
 
 
Table 2.  Scores obtained from the HET-CAM test. 
Test solution Score 
Saline 0.9% w/v (negative control) 0 
1M NaOH (positive control) pH14 3 
Unmedicated gel pH7.4 0 
Unmedicated gel pH7.8 1 
Medicated gel pH4.5 1 
Medicated gel pH7.4 0 
Medicated solution pH6.45 1 
Medicated solution pH4.75 2 
 
This semi-quantitative scoring method is still partially subjective, but does allow a 
number to be assigned to each test solution16.  The medicated solutions both scored 
higher values despite a lack of haemorrhage due to the turgidity of the yolk and 
vitelline membrane.  
 
In order to fully quantify the photographic results, the images were subjected to 
software analysis using Photoshop® and ImageJ.  The data was analysed and 
processed as a ‘grey value’ for each pixel along a uniform length (0 = black, 255 = 
white) i.e. a lower number correlates to more haemorrhaging (Figure 8).  All five 
replicates were analysed, and the averages plotted with standard deviations (Figures 9 
and 10). 
 
 
Figure 8.  An example profile plot on ImageJ, highlighting the correlation between 
dark blood vessels and lower greyscale values. 
 
Blood vessels 
 Figure 9.  Bar chart of the average grey value over distance for each of the test 
solutions (n = 5, ±SD). 
 
Figure 10.  Plot of the grey value over distance for each of the test solutions. 
The current ophthalmic solution has a pH beyond the limits of ocular tolerance of 6.6-
7.848-51 which produces minor eye irritation.  The HET-CAM tests demonstrate that 
the ophthalmic solution is also hypotonic, and causes discomfort from tissue swelling.  
As a result of these factors, and the chronic and laborious dosage schedule, 
compliance with the treatment can be poor.  The long-term outcomes of this non-
adherence to treatment can be serious, with blindness a potential end-point.   
 
The Organisation for Economic Co-operation and Development (OECD) Guideline 
405, entitled ‘Guidelines for the testing of chemicals; Acute eye irritation/corrosion’ 
states that, “Substances that have demonstrated corrosive or severe irritant properties 
in an in vitro or ex vivo test that has been validated and internationally accepted for 
the assessment specifically of eye corrosivity/irritation, need not be tested in animals. 
It can be presumed that such substances will produce similar severe effects in vivo”.  
The test has been validated by an EU Directive on dangerous substances. 
 
The HET-CAM test is useful as a model for ophthalmic tissue (such as the 
conjunctiva), since it is a functional membrane complete with vasculature and 
inflammatory responses, and can be evaluated for endpoints that are associated with 
ocular injuries.  The HET-CAM test evaluates the ability of a test substance to 
damage blood vessels, and cause haemorrhage, coagulation, hyperaemia or lysis.  The 
endpoints evaluated in the HET-CAM test method are different to those evaluated in 
the in vivo test method (discharge from the conjunctiva, redness and chemosis), but 
are thought to correlate well to the mechanisms of toxicity that could cause these in 
vivo endpoints. 
Of the three analysis methods used in this paper, qualitative, semi-quantitative and 
quantitative, none fully describes the effects of all the test solutions.  It is useful to 
include all three methods to allow a full and accurate description of the damage 
caused to the CAM.  The study demonstrates that the new gel formulation does not 
cause damage to the membranes of the CAM. 
 
4.0 Conclusions 
 
A new ophthalmic gel formulation has been developed to treat the corneal crystals 
associated with cystinosis.  As part of characterisation tests within our laboratories, 
the ocular irritation potential of the gel was determined using the HET-CAM test.  
The HET-CAM test uses the functional vasculature of the chicken’s placenta to 
represent the ophthalmic situation in vivo.  The new formulation outlined in this paper 
offers the possibility of a reduced daily dosage schedule (once or twice a day) and 
reduced ocular toxicity (zero score, non-irritant), which may improve patient 
compliance.  This in turn may improve long-term morbidity.  The HET-CAM tests 
demonstrate that the new formulation is safe for in vivo use. 
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